Physician profile
Joseph J Fallon
NPI 1760429369
$106,372.19
in general payments reported to CMS, 2019-2025
30 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $20K · 2021: $28K · 2022: $22K · 2023: $13K · 2024: $2,958 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $3,566 · Travel and Lodging: $2,331 · Education: $59.46 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,410.95 |
| Food and Beverage | $3,565.98 |
| Travel and Lodging | $2,330.87 |
| Education | $59.46 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59,905.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $13,713.78 | 2019 | |
| Mannkind Corporation | $7,618.65 | 2019-2024 | Afrezza |
| Esperion Therapeutics, INC. | $7,394.81 | 2021-2024 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $5,344.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,859.19 | 2021-2025 | |
| Ibsa Pharma INC. | $3,014.57 | 2019-2021 | |
| Medtronic, INC. | $1,800.96 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $548.24 | 2021-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $366.09 | 2021-2025 | Unithroid |
| Insulet Corporation | $252.78 | 2023-2024 | Omnipod |
| Amgen INC. | $229.82 | 2021-2024 | Tepezza |
| Sanofi-Aventis U.S. LLC | $153.24 | 2021-2023 | |
| Abbvie INC. | $149.59 | 2019-2025 | |
| Grt US Holding, INC. | $125.00 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $118.01 | 2022 | |
| Merck Sharp & Dohme LLC | $116.00 | 2023 | Verquvo |
| Intuity Medical INC | $108.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.30 | 2023 | Jardiance |
| Corcept Therapeutics | $101.30 | 2024 | Korlym |
| Lilly USA, LLC | $100.12 | 2019-2022 | |
| Valeritas, INC. | $97.62 | 2019 | |
| Nevro Corp. | $37.12 | 2023 | Senza |
| Ascendis Pharma Endocrinology INC | $33.32 | 2023-2025 | Yorvipath |
| Radius Health, INC. | $18.45 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.51 | 2025 | Gvoke Hypopen |
| Amryt Pharma Holdings LTD | $14.69 | 2023 | Myalept |
| Opko Pharmaceuticals, LLC | $14.36 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.91 | 2021 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Fallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.